Mepolizumab Under Review for Eosinophilic COPD
2024年12月11日 · The Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for mepolizumab as an add-on maintenance treatment for chronic …
Mepolizumab Significantly Reduces COPD Exacerbations
2024年9月12日 · Findings showed a statistically significant and clinically meaningful reduction in the annualized rate of moderate to severe exacerbations with mepolizumab compared with …
Mepolizumab reduces exacerbations in COPD with type 2 …
2024年9月16日 · Adding GSK’s mepolizumab to standard inhaled treatment reduces the frequency of moderate to severe exacerbations in chronic obstructive pulmonary disease …
Mepolizumab Under Review for Eosinophilic COPD - MPR
2024年12月9日 · The Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for mepolizumab as an add-on maintenance treatment for chronic …
FDA to review mepolizumab for COPD with eosinophilic …
2024年12月11日 · The FDA has accepted to review a supplemental new drug application for mepolizumab, an anti-IL-5 biologic, for treating patients with COPD plus an eosinophilic …
GSK announces positive results from phase III trial of Nucala ...
2024年9月6日 · GSK plc (LSE/NYSE: GSK) today announced positive headline results of MATINEE, the phase III clinical trial evaluating Nucala (mepolizumab), a monoclonal antibody …
FDA Accepts GSK’s Submission for Use of Mepolizumab in COPD
2024年12月9日 · GSK announced today that the US FDA has accepted for review its submission to extend the use of mepolizumab (Nucala) as an add-on maintenance treatment for people …
MATINEE: Mepolizumab Significantly Reduces COPD …
2024年9月9日 · Mepolizumab was found to significantly reduce exacerbations in adults with chronic obstructive pulmonary disease (COPD), according to results from the MATINEE trial.
Mepolizumab reduces exacerbation rates in patients with COPD
2024年7月10日 · SAN DIEGO — Among patients with COPD and heightened eosinophil levels, mepolizumab lowered annualized exacerbation rates, according to a presentation at the …
Nucala (mepolizumab) - News, Articles etc. - European …
2017年12月15日 · Nucala is the first biologic approved in the US for six- to 11-year-old children with severe eosinophilic asthma by the FDA. The FDA has expanded the approved use of …
- 某些结果已被删除